Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study

Abstract

Secukinumab is an interleukin (IL)-17A antagonist approved in 2015 by health agencies around the world for the treatment of moderate to severe plaque psoriasis in adult patients. Current knowledge of the efficacy and safety of secukinumab is limited to data from phase III randomized controlled trials (RCT). Despite the acceptable safety profile and promising efficacy results, there remains to be a lack of understanding of treatment outcomes in real-world clinical practice.

This article is protected by copyright. All rights reserved.

http://ift.tt/2tIUyWJ